Since 2016, Cureline, Inc., is a trusted partner of the Clinical Proteomic Tumor Analysis Consortium (CPTAC), a program under the National Cancer Institute (NCI, NIH) leadership aiming at better understanding of correlations between cancer genomics and proteins expression, modifications and functions. Cureline team has excelled in providing specimens and clinical data for complex molecular genomic and proteomic analyses by the program participants in a variety of indications including lung cancer, gastric carcinoma, melanoma, pancreatic cancer, AML, and soft tissue sarcoma among others.
       CPTAC is currently characterizing additional cancer types, expanding its application through open-source community resources, and accelerating precision oncology by applying proteogenomics to questions of toxicity and resistance in clinical trials. Based on CPTAC advancements, additional US-wide and international programs have been launched to investigate commonly diagnosed cancers with the goal of enhancing precision oncology and sharing data collected with scientists and physicians throughout the world. All program data (genomics, proteomics, imaging), assays, and reagents are made available to the public as a Community Resource to accelerate cancer research and advance patient care.